The trillion-dollar fat-loss drug
48:36–49:20 · 44s
Huberman previews retatrutide’s striking weight-loss results, why Eli Lilly will guard its patent, and how compounding pharmacies and gray markets complicate access.
48:36–49:20 · 44s
Huberman previews retatrutide’s striking weight-loss results, why Eli Lilly will guard its patent, and how compounding pharmacies and gray markets complicate access.
We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.